ANCA相关性血管炎相关眼眶炎性疾病的管理:系统文献综述
该系统综述评估了成人ANCA相关性血管炎相关眼眶炎性疾病(AAV-OID)的干预措施,纳入18项研究共277例患者,多数为回顾性队列。4项利妥昔单抗单药治疗系列显示,6个月时临床应答率达95%(95%CI 89-100%),缓解率达84%(95%CI 72-95%)。结论提示利妥昔单抗可能带来高缓解率,但需高质量前瞻性研究验证。
要点
- 利妥昔单抗单药治疗AAV-OID在6个月时临床应答率95%、缓解率84%。
- 纳入研究多为回顾性队列,多数涉及难治/复发病例,证据质量有限。
- 需开展高质量前瞻性研究以明确AAV-OID的最佳治疗策略。
核心结论
- 利妥昔单抗治疗AAV-OID可能获得高缓解率,但需高质量前瞻性研究进一步验证。
研究设计与样本
- 系统检索Embase、MEDLINE、Web of Science、ClinicalTrials.gov和Cochrane Central,无语言或日期限制。
- 纳入临床试验、病例对照研究、观察性研究和病例系列(≥5例)的成人AAV-OID治疗研究。
- 共筛选1001项研究,最终纳入18项(277例患者;14项回顾性队列,4项病例系列)。
- 多数研究(17/18)的Newcastle-Ottawa量表评分≥5分。
主要发现
- 多数研究涉及难治/复发病例。
- 4项利妥昔单抗单药治疗系列中,95%(95%CI 89-100%,p<0.001)的患者出现临床应答。
- 4项利妥昔单抗单药治疗系列中,84%(95%CI 72-95%,p<0.001)的患者在6个月时达到缓解。
关键数值与推荐
- 主要结局为临床应答,定义为体征或症状的任何改善,包括缓解。
- 次要结局包括缓解、复发、持续缓解(>6个月)和严重不良事件。
临床怎么用
- 对于AAV-OID患者,利妥昔单抗可作为考虑的治疗选择,尤其针对难治/复发病例。
- 临床决策时应结合患者具体情况,并认识到当前证据主要来自回顾性研究。
局限性
- 纳入研究多为回顾性队列,存在选择偏倚和信息偏倚风险。
- 多数研究涉及难治/复发病例,可能限制结果的外推性。
- 缺乏高质量前瞻性研究,无法确定最佳治疗方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Ocular manifestations frequently occur in ANCA-associated vasculitides (AAV). Orbital inflammatory disease (OID) is a subset with limited management guidelines. This systematic review evaluated interventions for AAV-OID. METHODS: We searched Embase, MEDLINE, Web of Science, ClinicalTrials.gov, and Cochrane Central without language or date restrictions for clinical trials, case-control studies, observational studies, and case series (≥5 patients) of adults treated for AAV-OID. Included studies reported therapy type and clinical response after ≥1 month. The primary outcome was clinical response, defined as any improvement in signs or symptoms, up to and including remission. Secondary outcomes included remission, relapse, sustained remission (>6 months), and serious adverse events. Two reviewers independently screened records and appraised studies using the Newcastle-Ottawa Scale (NOS). A qualitative synthesis and meta-analysis of proportions were performed using a random effects model. RESULTS: Of 1001 studies screened, 18 met inclusion criteria (277 patients; 14 retrospective cohorts, 4 case series). Most (17/18) had NOS scores ≥5. Thirteen studies included rituximab (RTX), 10 cyclophosphamide, 7 RTX + another immunosuppressant (IS), 11 conventional IS, and 7 surgical therapies. Most studies involved refractory/relapsing cases. In 4 RTX monotherapy series, 95% (95 %CI 89-100%, p < 0.001) had a clinical response and 84% (95%CI 72-95%, p < 0.001) achieved remission at 6 months. CONCLUSION: Our results suggest high remission rates of OID with RTX but highlight the need for high-quality prospective studies examining treatments for AAV-OID.
引用
- Neary E, Healey K, Clements-Baker M, et al. Management of antineutrophil cytoplasmic antibody vasculitis-associated orbital inflammatory disease: A systematic literature review. Semin Arthritis Rheum. 2025. PMID: 41456508. doi:10.1016/j.semarthrit.2025.152900
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。